Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · February 16, 2022

Effects of Dapagliflozin and Combination Therapy With Exenatide on Weight Loss in Type 2 Diabetes

The Journal of Clinical Endocrinology and Metabolism


Additional Info

The Journal of Clinical Endocrinology and Metabolism
Effects of dapagliflozin and combination therapy with exenatide on food-cue induced brain activation in patients with type 2 diabetes
J. Clin. Endocrinol. Metab. 2022 Feb 03;[EPub Ahead of Print], van Ruiten CC, Veltman DJ, Schrantee A, van Bloemendaal L, Barkhof F, Kramer MHH, Nieuwdorp M, IJzerman RG

Further Reading